BiVictriX Therapeutics Ltd
Biotechnology ResearchEngland, United Kingdom2-10 Employees
BiVictriX is redefining the next-generation of multispecific Antibody Drug Conjugates (ADCs) through precision, logic-gated targeting. We integrate high-resolution single-cell data to identify proprietary, disease-specific cell surface signatures present on the key pathogenic cells driving disease. Through our conditional logic-gated ADC platform, we design BI-CYGNI™ ADCs that selectively eliminate these cells - and only these cells - driving deeper and more durable regressions. Our approach further drives synergistic cell killing across both high- and low dual antigen–expressing tumors, expanding patient eligibility within heterogeneous disease while preserving safety. BiVictriX is advancing an expanding pipeline of BI-CYGNI™ ADCs addressing areas of high unmet need across solid tumours and haematological malignancies.
1-888-653-2347 
support@leadiq.com 
